A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (927 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: cancerchemotherapytherapymalignanciesto determine
  Phrases that lowered it: adpainsubjectsthe efficacyevaluate the
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Phase: 3 (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Sponsor's past trials: 1 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients NCT00684632 · started 2008 · scored riskier than 12% of active trials completed
• Sublingual Fentanyl for the Management of Breakthrough Pain NCT02514252 · started 2016 · scored riskier than 99% of active trials terminated
• Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain NCT00813488 · started 2008 · scored riskier than 37% of active trials completed
• A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain NCT01429051 · started 2011 · scored riskier than 43% of active trials completed
• A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain NCT00833040 · started 2009 · scored riskier than 17% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.